Dimple Chakravarty, PhD
About Me
Dr. Dimple Chakravarty is an Assistant Professor in the Department of Urology at the Icahn School of Medicine. Before joining Mount Sinai, she was a faculty member in the GU oncology department at UT MD Anderson Cancer Center and the Department of Pathology at Weill Cornell. Her training and expertise are in the field of genomics and cancer biology. She has extensive experience in functional genomics, proteomics, and RNA biology (long and small non-coding RNA). She uses multiple biological systems for her research, including cell lines, organoids, and animal models. Dr. Chakravarty's laboratory focuses on understanding genetic, immunological, and epigenetic factors that contribute to prostate cancer progression and aggressiveness using next-generation sequencing approaches and in-vitro and in-vivo models such as patient-derived xenografts and organoids, and cell line-based models to develop potential therapeutic strategies. She led the first studies discovering NEAT1-lncRNA as an essential driver of prostate cancer progression and an inventor of a patent "NEAT1 as a prognostic marker and therapeutic target for prostate cancer". Her lab is invested in understanding the androgen receptor signaling in prostate cancer and immune modulation and she is a research PI on a clinical trial focused on evaluating the efficacy of antiandrogen and immunotherapy in molecularly stratified patients with high-risk prostate cancer. Over the past 15 years, she has mentored several undergraduates, postgraduate, and Ph.D. candidates. She has also led a team of clinicians, researchers, biostatisticians, and clinical fellows for the successful execution of several clinical trials.
Language
Position
About Me
Dr. Dimple Chakravarty is an Assistant Professor in the Department of Urology at the Icahn School of Medicine. Before joining Mount Sinai, she was a faculty member in the GU oncology department at UT MD Anderson Cancer Center and the Department of Pathology at Weill Cornell. Her training and expertise are in the field of genomics and cancer biology. She has extensive experience in functional genomics, proteomics, and RNA biology (long and small non-coding RNA). She uses multiple biological systems for her research, including cell lines, organoids, and animal models. Dr. Chakravarty's laboratory focuses on understanding genetic, immunological, and epigenetic factors that contribute to prostate cancer progression and aggressiveness using next-generation sequencing approaches and in-vitro and in-vivo models such as patient-derived xenografts and organoids, and cell line-based models to develop potential therapeutic strategies. She led the first studies discovering NEAT1-lncRNA as an essential driver of prostate cancer progression and an inventor of a patent "NEAT1 as a prognostic marker and therapeutic target for prostate cancer". Her lab is invested in understanding the androgen receptor signaling in prostate cancer and immune modulation and she is a research PI on a clinical trial focused on evaluating the efficacy of antiandrogen and immunotherapy in molecularly stratified patients with high-risk prostate cancer. Over the past 15 years, she has mentored several undergraduates, postgraduate, and Ph.D. candidates. She has also led a team of clinicians, researchers, biostatisticians, and clinical fellows for the successful execution of several clinical trials.